Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system

Peter Hosein, Ana Echenique, Arturo Loaiza-Bonilla, Tatiana Froud, Katuzka Barbery, Caio M. Rocha Lima, Jose Yrizarry, Govindarajan Narayanan

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose To describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM). Materials and Methods A retrospective analysis of patients undergoing IRE for the management of CLM was performed. Procedures were done percutaneously under general anesthesia. Patients were then followed for adverse events, tumor response, and survival. Results Between March 2010 and February 2013, 29 patients underwent percutaneous ablation of 58 tumors in 36 IRE sessions. Most patients (89%) had an absolute or relative contraindication to thermal ablation. The median age was 62 years, and the median time from diagnosis to IRE was 28 months. The median number of lesions treated per patient was two, and the median tumor size was 2.7 cm. Patients had received previous chemotherapy regimens (range, 1-5 per patient). A new Metabolic Imaging And Marker Integration response evaluation criteria was used for response assessment, and was a predictor of progression-free and overall survival. The 2-year progression-free survival rate was 18% (95% confidence interval, 0%-35%), and the 2-year overall survival rate was 62% (95% confidence interval, 37%-87%). Complications included arrhythmias (n = 1) and postprocedure pain (n = 1). Both patients recovered without sequelae. Conclusions Percutaneous IRE of CLM is feasible and safe. A new response evaluation system for colorectal cancer appears to be prognostic.

Original languageEnglish
Pages (from-to)1233-1239
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume25
Issue number8
DOIs
StatePublished - Jan 1 2014

Fingerprint

Electroporation
Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Therapeutics
Disease-Free Survival
Liver
Survival Rate
Confidence Intervals
Neoplasms
General Anesthesia
Cardiac Arrhythmias
Hot Temperature
Drug Therapy
Pain
Survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. / Hosein, Peter; Echenique, Ana; Loaiza-Bonilla, Arturo; Froud, Tatiana; Barbery, Katuzka; Rocha Lima, Caio M.; Yrizarry, Jose; Narayanan, Govindarajan.

In: Journal of Vascular and Interventional Radiology, Vol. 25, No. 8, 01.01.2014, p. 1233-1239.

Research output: Contribution to journalArticle

Hosein, Peter ; Echenique, Ana ; Loaiza-Bonilla, Arturo ; Froud, Tatiana ; Barbery, Katuzka ; Rocha Lima, Caio M. ; Yrizarry, Jose ; Narayanan, Govindarajan. / Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. In: Journal of Vascular and Interventional Radiology. 2014 ; Vol. 25, No. 8. pp. 1233-1239.
@article{9f13a4403bd14305940d019605595e37,
title = "Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system",
abstract = "Purpose To describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM). Materials and Methods A retrospective analysis of patients undergoing IRE for the management of CLM was performed. Procedures were done percutaneously under general anesthesia. Patients were then followed for adverse events, tumor response, and survival. Results Between March 2010 and February 2013, 29 patients underwent percutaneous ablation of 58 tumors in 36 IRE sessions. Most patients (89{\%}) had an absolute or relative contraindication to thermal ablation. The median age was 62 years, and the median time from diagnosis to IRE was 28 months. The median number of lesions treated per patient was two, and the median tumor size was 2.7 cm. Patients had received previous chemotherapy regimens (range, 1-5 per patient). A new Metabolic Imaging And Marker Integration response evaluation criteria was used for response assessment, and was a predictor of progression-free and overall survival. The 2-year progression-free survival rate was 18{\%} (95{\%} confidence interval, 0{\%}-35{\%}), and the 2-year overall survival rate was 62{\%} (95{\%} confidence interval, 37{\%}-87{\%}). Complications included arrhythmias (n = 1) and postprocedure pain (n = 1). Both patients recovered without sequelae. Conclusions Percutaneous IRE of CLM is feasible and safe. A new response evaluation system for colorectal cancer appears to be prognostic.",
author = "Peter Hosein and Ana Echenique and Arturo Loaiza-Bonilla and Tatiana Froud and Katuzka Barbery and {Rocha Lima}, {Caio M.} and Jose Yrizarry and Govindarajan Narayanan",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jvir.2014.04.007",
language = "English",
volume = "25",
pages = "1233--1239",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system

AU - Hosein, Peter

AU - Echenique, Ana

AU - Loaiza-Bonilla, Arturo

AU - Froud, Tatiana

AU - Barbery, Katuzka

AU - Rocha Lima, Caio M.

AU - Yrizarry, Jose

AU - Narayanan, Govindarajan

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose To describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM). Materials and Methods A retrospective analysis of patients undergoing IRE for the management of CLM was performed. Procedures were done percutaneously under general anesthesia. Patients were then followed for adverse events, tumor response, and survival. Results Between March 2010 and February 2013, 29 patients underwent percutaneous ablation of 58 tumors in 36 IRE sessions. Most patients (89%) had an absolute or relative contraindication to thermal ablation. The median age was 62 years, and the median time from diagnosis to IRE was 28 months. The median number of lesions treated per patient was two, and the median tumor size was 2.7 cm. Patients had received previous chemotherapy regimens (range, 1-5 per patient). A new Metabolic Imaging And Marker Integration response evaluation criteria was used for response assessment, and was a predictor of progression-free and overall survival. The 2-year progression-free survival rate was 18% (95% confidence interval, 0%-35%), and the 2-year overall survival rate was 62% (95% confidence interval, 37%-87%). Complications included arrhythmias (n = 1) and postprocedure pain (n = 1). Both patients recovered without sequelae. Conclusions Percutaneous IRE of CLM is feasible and safe. A new response evaluation system for colorectal cancer appears to be prognostic.

AB - Purpose To describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM). Materials and Methods A retrospective analysis of patients undergoing IRE for the management of CLM was performed. Procedures were done percutaneously under general anesthesia. Patients were then followed for adverse events, tumor response, and survival. Results Between March 2010 and February 2013, 29 patients underwent percutaneous ablation of 58 tumors in 36 IRE sessions. Most patients (89%) had an absolute or relative contraindication to thermal ablation. The median age was 62 years, and the median time from diagnosis to IRE was 28 months. The median number of lesions treated per patient was two, and the median tumor size was 2.7 cm. Patients had received previous chemotherapy regimens (range, 1-5 per patient). A new Metabolic Imaging And Marker Integration response evaluation criteria was used for response assessment, and was a predictor of progression-free and overall survival. The 2-year progression-free survival rate was 18% (95% confidence interval, 0%-35%), and the 2-year overall survival rate was 62% (95% confidence interval, 37%-87%). Complications included arrhythmias (n = 1) and postprocedure pain (n = 1). Both patients recovered without sequelae. Conclusions Percutaneous IRE of CLM is feasible and safe. A new response evaluation system for colorectal cancer appears to be prognostic.

UR - http://www.scopus.com/inward/record.url?scp=84905271642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905271642&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2014.04.007

DO - 10.1016/j.jvir.2014.04.007

M3 - Article

C2 - 24861662

AN - SCOPUS:84905271642

VL - 25

SP - 1233

EP - 1239

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 8

ER -